Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor

Reuters

Feb 10

Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor

Agenus Inc. hat angekündigt, neue translationale und klinische Biomarker-Analysen aus dem Botensilimab (BOT)-Immuntherapieprogramm auf der American Association for Cancer Research–Immuno-Oncology (AACR-IO) Konferenz vom 18. bis 21. Februar 2026 in Los Angeles vorzustellen. Die Forschungsdaten untersuchen, wie systemische Entzündungsmarker, immunologische Aktivität im Tumormikromilieu und periphere Immunzellzustände mit klinischen Ergebnissen bei Patienten mit immunologisch „kalten“, therapieresistenten Tumoren unter Behandlung mit Botensilimab allein oder in Kombination mit Balstilimab $(BAL)$ zusammenhängen. Die Ergebnisse werden in einer Posterpräsentation am 19. Februar 2026 vorgestellt.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209269639) on February 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610650919"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610650919\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610650919?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-10 02:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610650919","market":"nz","top_or_hot":-1,"title":"Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. hat angekündigt, neue translationale und klinische Biomarker-Analysen aus dem Botensilimab (BOT)-Immuntherapieprogramm auf der American Association for Cancer Research–Immuno-Oncology (AACR-IO) Konferenz vom 18. bis 21. Februar 2026 in Los Angeles vorzustellen. Die Forschungsdaten untersuchen, wie systemische Entzündungsmarker, immunologische Aktivität im Tumormikromilieu und periphere Immunzellzustände mit klinischen Ergebnissen bei Patienten mit immunologisch „kalten“, therapieresistenten Tumoren unter Behandlung mit Botensilimab allein oder in Kombination mit Balstilimab <a href=\"https://laohu8.com/S/BAL\">$(BAL)$</a> zusammenhängen. Die Ergebnisse werden in einer Posterpräsentation am 19. Februar 2026 vorgestellt.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209269639) on February 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-10 02:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. hat angekündigt, neue translationale und klinische Biomarker-Analysen aus dem Botensilimab (BOT)-Immuntherapieprogramm auf der American Association for Cancer Research–Immuno-Oncology (AACR-IO) Konferenz vom 18. bis 21. Februar 2026 in Los Angeles vorzustellen. Die Forschungsdaten untersuchen, wie systemische Entzündungsmarker, immunologische Aktivität im Tumormikromilieu und periphere Immunzellzustände mit klinischen Ergebnissen bei Patienten mit immunologisch „kalten“, therapieresistenten Tumoren unter Behandlung mit Botensilimab allein oder in Kombination mit Balstilimab <a href=\"https://laohu8.com/S/BAL\">$(BAL)$</a> zusammenhängen. Die Ergebnisse werden in einer Posterpräsentation am 19. Februar 2026 vorgestellt.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209269639) on February 09, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDLc92SBb:1","article_id":"2610650919","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610650919","pubTimestamp":1770660024,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire  on February 09, 2026, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AGEN":"艾吉纳斯公司"},"translate_title":"Agenus公布Botensilimab治疗耐药肿瘤的新临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":0.9},"content_text":"Agenus stellt neue klinische Daten zu Botensilimab bei therapieresistenten Tumoren vor\n    \n\n        Agenus Inc. hat angekündigt, neue translationale und klinische Biomarker-Analysen aus dem Botensilimab (BOT)-Immuntherapieprogramm auf der American Association for Cancer Research–Immuno-Oncology (AACR-IO) Konferenz vom 18. bis 21. Februar 2026 in Los Angeles vorzustellen. Die Forschungsdaten untersuchen, wie systemische Entzündungsmarker, immunologische Aktivität im Tumormikromilieu und periphere Immunzellzustände mit klinischen Ergebnissen bei Patienten mit immunologisch „kalten“, therapieresistenten Tumoren unter Behandlung mit Botensilimab allein oder in Kombination mit Balstilimab $(BAL)$ zusammenhängen. Die Ergebnisse werden in einer Posterpräsentation am 19. Februar 2026 vorgestellt.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260209269639) on February 09, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}